These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

81 related items for PubMed ID: 23007573

  • 1. Impact of biomarkers on clinical trial risk in breast cancer.
    Parker JL, Lushina N, Bal PS, Petrella T, Dent R, Lopes G.
    Breast Cancer Res Treat; 2012 Nov; 136(1):179-85. PubMed ID: 23007573
    [Abstract] [Full Text] [Related]

  • 2. Phosphorylated/activated HER2 as a marker of clinical resistance to single agent taxane chemotherapy for metastatic breast cancer.
    Modi S, DiGiovanna MP, Lu Z, Moskowitz C, Panageas KS, Van Poznak C, Hudis CA, Norton L, Tan L, Stern DF, Carter D, Seidman AD.
    Cancer Invest; 2005 Nov; 23(6):483-7. PubMed ID: 16203655
    [Abstract] [Full Text] [Related]

  • 3. Capecitabine after anthracycline and taxane exposure in HER2-negative metastatic breast cancer patients: response, survival and prognostic factors.
    Gilabert M, Bertucci F, Esterni B, Madroszyk A, Tarpin C, Jacquemier J, Extra JM, Viens P, Gonçalves A.
    Anticancer Res; 2011 Mar; 31(3):1079-86. PubMed ID: 21498742
    [Abstract] [Full Text] [Related]

  • 4. HER2/CEP17 ratio and HER2 immunohistochemistry predict clinical outcome after first-line trastuzumab plus taxane chemotherapy in patients with HER2 fluorescence in situ hybridization-positive metastatic breast cancer.
    Kim JW, Kim JH, Im SA, Kim YJ, Han HS, Kim JS, Lee KH, Kim TY, Han SW, Jeon YK, Oh DY, Kim TY, Park IA.
    Cancer Chemother Pharmacol; 2013 Jul; 72(1):109-15. PubMed ID: 23673443
    [Abstract] [Full Text] [Related]

  • 5. Biomarkers and receptor targeted therapies reduce clinical trial risk in non-small-cell lung cancer.
    Falconi A, Lopes G, Parker JL.
    J Thorac Oncol; 2014 Feb; 9(2):163-9. PubMed ID: 24419412
    [Abstract] [Full Text] [Related]

  • 6. Evidence-based use of neoadjuvant taxane in operable and inoperable breast cancer.
    Estévez LG, Gradishar WJ.
    Clin Cancer Res; 2004 May 15; 10(10):3249-61. PubMed ID: 15161677
    [Abstract] [Full Text] [Related]

  • 7. Cost comparison of capecitabine in patients with breast cancer.
    Rugo HS, Kohles J, Schulman KL.
    Am J Clin Oncol; 2010 Dec 15; 33(6):550-6. PubMed ID: 20051811
    [Abstract] [Full Text] [Related]

  • 8. Lapatinib versus trastuzumab in combination with neoadjuvant anthracycline-taxane-based chemotherapy (GeparQuinto, GBG 44): a randomised phase 3 trial.
    Untch M, Loibl S, Bischoff J, Eidtmann H, Kaufmann M, Blohmer JU, Hilfrich J, Strumberg D, Fasching PA, Kreienberg R, Tesch H, Hanusch C, Gerber B, Rezai M, Jackisch C, Huober J, Kühn T, Nekljudova V, von Minckwitz G, German Breast Group (GBG), Arbeitsgemeinschaft Gynäkologische Onkologie-Breast (AGO-B) Study Group.
    Lancet Oncol; 2012 Feb 15; 13(2):135-44. PubMed ID: 22257523
    [Abstract] [Full Text] [Related]

  • 9. The role of anthracyclines in the treatment of early breast cancer.
    Greene J, Hennessy B.
    J Oncol Pharm Pract; 2015 Jun 15; 21(3):201-12. PubMed ID: 24769570
    [Abstract] [Full Text] [Related]

  • 10. [Chemotherapy for breast cancer refractory to anthracycline, taxane or trastuzumab].
    Ito Y, Kobayashi K.
    Gan To Kagaku Ryoho; 2009 May 15; 36(5):726-9. PubMed ID: 19461171
    [Abstract] [Full Text] [Related]

  • 11. Lapatinib or Trastuzumab Plus Taxane Therapy for Human Epidermal Growth Factor Receptor 2-Positive Advanced Breast Cancer: Final Results of NCIC CTG MA.31.
    Gelmon KA, Boyle FM, Kaufman B, Huntsman DG, Manikhas A, Di Leo A, Martin M, Schwartzberg LS, Lemieux J, Aparicio S, Shepherd LE, Dent S, Ellard SL, Tonkin K, Pritchard KI, Whelan TJ, Nomikos D, Nusch A, Coleman RE, Mukai H, Tjulandin S, Khasanov R, Rizel S, Connor AP, Santillana SL, Chapman JA, Parulekar WR.
    J Clin Oncol; 2015 May 10; 33(14):1574-83. PubMed ID: 25779558
    [Abstract] [Full Text] [Related]

  • 12. Lessons learned from independent central review.
    Ford R, Schwartz L, Dancey J, Dodd LE, Eisenhauer EA, Gwyther S, Rubinstein L, Sargent D, Shankar L, Therasse P, Verweij J.
    Eur J Cancer; 2009 Jan 10; 45(2):268-74. PubMed ID: 19101138
    [Abstract] [Full Text] [Related]

  • 13. Safety and efficacy of first-line bevacizumab combined with taxane therapy in Chinese patients with HER2-negative locally recurrent or metastatic breast cancer: findings from the ATHENA study.
    Xu BH, Jiang ZF, Shen ZZ, Guan ZZ, Chen ZD, Cheng Y, Zheng H, Jiang J, Wang XJ, Tong ZS, Qin SK, Luo Y, Yao M, Wang LW, He J.
    Chin Med J (Engl); 2012 Mar 10; 125(5):764-9. PubMed ID: 22490570
    [Abstract] [Full Text] [Related]

  • 14. A phase II study of trastuzumab emtansine in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer who were previously treated with trastuzumab, lapatinib, an anthracycline, a taxane, and capecitabine.
    Krop IE, LoRusso P, Miller KD, Modi S, Yardley D, Rodriguez G, Guardino E, Lu M, Zheng M, Girish S, Amler L, Winer EP, Rugo HS.
    J Clin Oncol; 2012 Sep 10; 30(26):3234-41. PubMed ID: 22649126
    [Abstract] [Full Text] [Related]

  • 15. The clinical significance of Ki-67 as a marker of prognostic value and chemosensitivity prediction in hormone-receptor-positive breast cancer: a meta-analysis of the published literature.
    Liu Y, Yin W, Yan T, Du Y, Shao Z, Lu J.
    Curr Med Res Opin; 2013 Nov 10; 29(11):1453-61. PubMed ID: 23927551
    [Abstract] [Full Text] [Related]

  • 16. Pyrotinib: First Global Approval.
    Blair HA.
    Drugs; 2018 Nov 10; 78(16):1751-1755. PubMed ID: 30341682
    [Abstract] [Full Text] [Related]

  • 17. Cardiovascular risk profile of patients with HER2/neu-positive breast cancer treated with anthracycline-taxane-containing adjuvant chemotherapy and/or trastuzumab.
    Jones LW, Haykowsky M, Peddle CJ, Joy AA, Pituskin EN, Tkachuk LM, Courneya KS, Slamon DJ, Mackey JR.
    Cancer Epidemiol Biomarkers Prev; 2007 May 10; 16(5):1026-31. PubMed ID: 17507633
    [Abstract] [Full Text] [Related]

  • 18. Updates in anti-HER2 combination therapy.
    Burstein H.
    Clin Adv Hematol Oncol; 2008 Dec 10; 6(12):873-4. PubMed ID: 19209136
    [No Abstract] [Full Text] [Related]

  • 19. Role of anthracyclines in the treatment of early breast cancer.
    Gianni L, Norton L, Wolmark N, Suter TM, Bonadonna G, Hortobagyi GN.
    J Clin Oncol; 2009 Oct 01; 27(28):4798-808. PubMed ID: 19687331
    [Abstract] [Full Text] [Related]

  • 20. Cost effectiveness of ixabepilone plus capecitabine for metastatic breast cancer progressing after anthracycline and taxane treatment.
    Reed SD, Li Y, Anstrom KJ, Schulman KA.
    J Clin Oncol; 2009 May 01; 27(13):2185-91. PubMed ID: 19332722
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 5.